This piece is authored by Chris Morris, writing for CNBC, a sort of WSJ online, and therefore there’s not much editorial room to castigate Big Pharma as it deserves, but even Morris manages to say this at the very outset: “As outrageous as the cost of health care can be in the United States, it’s nothing compared to the markup on some prescription medicines. While companies certainly have to recoup their research and development costs and earn a profit for investors — and the exclusive window before a generic version of a drug goes on sale is the optimal time to do so — those prices can sometimes get out of hand.”
Which, again, is putting it very very mildly.